GlaxoSmithKline (GSK) has welcomed the listing of Incruse Ellipta (umeclidinium) on the Australian Pharmaceutical Benefits Scheme (PBS) from December 1st 2014 as a long term once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) which is also known as chronic bronchitis, “smoker’s cough” or emphysema. 

Incruse Ellipta is a once-daily treatment containing umeclidinium, a long-acting muscarinic antagonist (LAMA), delivered by the Ellipta inhaler. 

Australian respiratory specialist and clinical researcher Professor Peter Frith from Repatriation General Hospital said COPD can be a debilitating disease and he welcomed the improved access to new treatments that results from PBS reimbursement. 

“I certainly welcome better access to effective treatment options in COPD that can alleviate symptoms and improve quality of life,” said Professor Frith.

For more details, go to: http://www.gsk.com.au/media-centre_detail.aspx?view=789